The Senate Finance Committee today held a hearing for Alex Azar, President Trump’s nominee for secretary of Health and Human Services. Azar, former president of Lilly USA and deputy HHS secretary under the George W. Bush administration, faced a number of questions from senators about his ties to the pharmaceutical industry and how he would tackle high drug prices. If confirmed, Azar said he would focus his efforts on addressing the high cost of drugs; making health care more affordable, available and “tailored to what individuals want and need in their care”; harnessing “the power of Medicare to shift the focus in our health care system from paying for procedures and sickness to paying for health and outcomes”; and tackling “the scourge of the opioid epidemic.” Tom Price, M.D., resigned as HHS secretary last September. Deputy Secretary Eric Hargan has been serving as acting secretary.

Headline
The Trump administration announced Aug. 31 agreements with nine additional pharmaceutical manufacturers aimed at lowering prescription drug prices through a…
Headline
This webinar explores how hospital and health system leaders can prepare for Medicare Advantage’s new electronic prior authorization mandate, which goes into…
Headline
A new AHA blog details how hospitals are modernizing care for older Americans. It highlights the Age-Friendly Health Systems initiative, created by The John A…
Headline
The AHA Aug. 17 provided comments to the Centers for Medicare & Medicaid Services on its proposed rule to codify in regulation the Medicare Drug Price…
Headline
The AHA’s Community Health Improvement network will host a webinar Aug. 26 at noon ET that will feature discussion from leaders at CredibleMind on what a…
Headline
In this conversation, Baligh Yehia, M.D., president of Jefferson Health, shares how the organization is rethinking healthcare access through same-day cancer…